Full Text View
Tabular View
No Study Results Posted
Related Studies
Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.
This study is currently recruiting participants.
Verified January 2012 by Novartis

First Received on December 17, 2009.   Last Updated on January 26, 2012   History of Changes
Sponsor: Novartis Pharmaceuticals
Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01035229
  Purpose

The purpose of this study is to compare treatment with RAD001 plus best supportive care (BSC) to placebo plus BSC in patients with advanced HCC whose disease progressed while on or after sorafenib treatment or who are intolerant to sorafenib.


Condition Intervention Phase
Carcinoma
 Drug: Everolimus
 Phase III

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Phase III, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Everolimus (RAD001) in Adult Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment - The EVOLVE-1 Study

Resource links provided by NLM:

MedlinePlus related topics: Cancer
Drug Information available for: Sirolimus Everolimus CCI 779
U.S. FDA Resources

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Overall Survival [ Time Frame: Until all patients have disease progression or leave study due to intolerable advese events- Estimate of 1 year for each patient. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time to tumor progression (TTP) [ Time Frame: Until all patients have disease progression or leave study due to intolerable advese events- Estimate of 1 year for each patient ] [ Designated as safety issue: No ]
  • Disease control rate (DCR) [ Time Frame: Until all patients have disease progression or leave study due to intolerable advese events- Estimate of 1 year for each patient ] [ Designated as safety issue: No ]
  • Change in Eastern Cooperative Oncology Group (ECOG) performance status over time [ Time Frame: Until all patients have disease progression or leave study due to intolerable advese events- Estimate of 1 year for each patient. ] [ Designated as safety issue: No ]
  • Safety [ Time Frame: Until all patients have disease progression or leave study due to intolerable advese events- Estimate of 1 year for each patient. ] [ Designated as safety issue: Yes ]
  • Change in quality of life (QoL) scores over time [ Time Frame: Until all patients have disease progression or leave study due to intolerable advese events- Estimate of 1 year for each patient. ] [ Designated as safety issue: No ]
  • Pharmacokinetics assessments [ Time Frame: Until all patients have disease progression or leave study due to intolerable advese events- Estimate of 1 year for each patient. ] [ Designated as safety issue: No ]

Estimated Enrollment: 531
Study Start Date: May 2010
Estimated Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Everolimus plus Basic Supportice Care Drug: Everolimus
3 tablets a da for one year
Other Name: RAD001
Placebo Comparator: Placebo plus Basic Supportive Care Drug: Everolimus
3 tablets a da for one year
Other Name: RAD001

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Advanced liver cancer

  2. Prior systemic treatment with sorafenib for advanced HCC and for whom their disease progressed during or after sorafenib treatment, or were intolerant to sorafenib treatment. Specifically, this can be defined as:

    • Documented radiological confirmation (radiology scans or report) of disease progression during or after sorafenib treatment
    • Intolerance to sorafenib (at any dose and/or duration) is defined as documented sorafenib-related grade 3 or 4 adverse events that led to sorafenib discontinuation.

    NOTE:

    • Sorafenib must be the last antineoplastic treatment before randomization
    • Prior local and/or hormonal therapy (e.g., tamoxifen) before sorafenib is allowed
    • One systemic chemotherapy regimen for advanced HCC is allowed before sorafenib treatment
  3. ECOG performance status of ≤ 2
  4. Child-Pugh A

Exclusion Criteria:

  • Active bleeding during the last 28 days
  • Prior therapy with mTOR inhibitors
  • Prior liver or other organ transplantation which mandates systemic immunosuppression Other protocol-defined inclusion/exclusion criteria may apply
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01035229

Contacts
Contact: Novartis Pharmaceuticals +1-800-340-6843

  Show 37 Study Locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Additional Information:
Related Info  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01035229     History of Changes
Other Study ID Numbers: CRAD001O2301
Study First Received: December 17, 2009
Last Updated: January 26, 2012
Health Authority: United States: Food and Drug Administration;   Austria: Ethikkommission;   Belgium: Institutional Review Board;   France: Afssaps - French Health Products Safety Agency;   Hungary: Institutional Ethics Committee;   Greece: Ethics Committee;   Italy: Ethics Committee;   Germany: German Institute of Medical Documentation and Information;   Spain: Ministry of Health;   Sweden: Institutional Review Board;   Canada: Health Canada;   Japan: Institutional Review Board;   Australia: Department of Health and Ageing Therapeutic Goods Administration;   China: Ethics Committee;   Hong Kong: Department of Health;   Korea: Food and Drug Administration;   Israel: Ministry of Health

Keywords provided by Novartis:
Hepatocellular carcinoma
randomized trial
medical treatment
 RAD001
placebo
Advanced Hepatocellular Carcinoma (HCC)

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Everolimus
 Sirolimus
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Antifungal Agents
Anti-Infective Agents
Anti-Bacterial Agents

ClinicalTrials.gov processed this record on February 09, 2012



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services